carbon monoxide has been researched along with nintedanib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bi, Y; Chowdhury, BA; Karimi-Shah, BA; Paterniti, MO; Rekić, D; Wang, Y | 1 |
| Bacchi Reggiani, ML; Bandelli, G; Bassi, I; Betti, S; Carpano, M; Cerri, S; Clini, E; Donatelli, P; Garuti, M; Guerrieri, A; Luppi, F; Monari, M; Nava, S; Tonelli, R | 1 |
2 other study(ies) available for carbon monoxide and nintedanib
| Article | Year |
|---|---|
Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Carbon Monoxide; Disease Progression; Female; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Male; Middle Aged; Multivariate Analysis; Pyridones; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome; Vital Capacity | 2017 |
Real-life comparison of pirfenidone and nintedanib in patients with idiopathic pulmonary fibrosis: A 24-month assessment.
Topics: Carbon Monoxide; Humans; Idiopathic Pulmonary Fibrosis; Indoles; Lung; Pyridones; Time Factors; Vital Capacity | 2019 |